PURA Reports $3M Trailing 12 Months Revenue And Expansion Into $500B Market
August 25 2020 - 9:02AM
InvestorsHub NewsWire
Dallas, TX
-- August 25, 2020 -- InvestorsHub
NewsWire
- 48% YTD Revenue Growth From CBD Beverage
Sales
- $500 Billion Horizontal Market
Expansion
- Pending 1 For 1 Shareholder
Dividend
- Surprise Additional 1 For 1 Shareholder
Dividend Opportunity
Puration, Inc. (USOTC:
PURA) today highlighted the company has exceeded $3 million in
revenue over the trailing 12 months. Last week, the company
published its Q2 2020 financials reporting $1.6 million in sales
year-to-date (YTD) representing 48% revenue growth compared to the
same period last year. Today, management is publishing a
comprehensive update that includes a review of the Q2 2020 report
and the latest information on a pending 1 for 1 dividend
anticipated to be issued soon to PURA shareholders in addition to
new information on a surprise second 1 for 1 dividend
opportunity. The report also includes the latest on the
company’s ongoing acquisition campaign to expand horizontally from
its existing CBD infused beverage market into an addition $500
billion market opportunity. The update is included in its
entirety below:
PURA Q2 2020 48% YTD Sales
Growth
PURA remains resilient through the
COVID-19 Pandemic reporting 48% sales growth YTD compared to the
same period last year. The company realized $1.6 million in
revenue with $471,000 in gross profit primarily from sales of its
EVERx CBD Sports Water. PURA expects to maintain resilient
sales throughout the year.
At the same time the company continues to
position itself as an overall CBD infused consumer products company
through its ongoing acquisition
campaign.
PURA CBD Infused Consumer Products
Acquisition Campaign
In January of
this year, PURA initiated an acquisition campaign to introduce a
solution to the cannabis sector-wide challenge with access to
capital by leveraging its own core competencies to acquire CBD
infused beverage, edible and topical
businesses.
PURA targets
CBD product acquisitions that can be enhanced with PURA's patented
technology. PURA owns a license to a U.S. Patented cannabis
extraction process backed by extensive university medical research.
The license, issued by NCM Biotech, is exclusive for beverages,
edibles and cosmetics among other uses. NCM Biotech is focused on
medical research and Puration has access to that research. See a
recent research report on CBD extracts derived from NCM Biotech's
patented extraction process: Journal of Cannabis
Research.
Since
launching the acquisition campaign in January, the company has
acquired a CBD confections business, a CBD pet products business
and CBD sun care business. Combined with its existing
beverage industry product line, PURA's combined horizontal market
opportunity ranges across over $2 trillion in market
value:
Sexual wellness
$39
Billion Projected Market
Value
Confections
$232
Billion Projected Market
Value
Pet
Products $202
Billion Projected Market
Value
Sun
Care $12.6
Billion Projected Market
Value
Non-Alcoholic
Beverage $1.6
Trillion Projected Market
Value
In conjunction
with the acquisition campaign, PURA secured a $5
million investment to fund its acquisition efforts. PURA
concentrates on making acquisitions in exchange for royalty
agreements and a commitment for PURA to fund a marketing expansion
of the product line.
PURA is
developing a single brand name identity and unified marketing
strategy that can cross all five industries listed above in
addition to any new industries PURA may enter with future
acquisitions. PURA plans to release the latest information
regarding its branding and market strategy developments next
week.
PURA 1 For 1 Stock
Dividend
On August
11th, 2020, PURA announced a declaration of a stock
dividend. The planned dividend distribution to PURA shareholders
results from the recent sale of PURA's cannabis cultivation
operation. A prompt dividend distribution date of record is pending
approval and anticipated to be announced very soon. The plan is
also to pay the dividend
promptly.
The cannabis
cultivation operation was sold two weeks ago in exchange for common
stock in another public company. The stock is slated to be
distributed to PURA shareholders in a dividend distribution. The
planned distribution ratio is 1 for
1.
Surprise
Additional 1 For 1 Dividend
Opportunity
Last week, PURA
announced a potential deal in the works to sell the company's water
purification technology.
Prior to
entering into the cannabis marketplace with the acquisition of
patented cannabis extraction process licenses, PURA worked in the
development of proprietary water purification technologies. In
fact, PURA's legacy personal water purification product, Filter2Go
remains for sale online to include distribution
through Amazon.com.
Recently, PURA
has been approached by a party looking to acquire PURA's legacy
water purification assets. The deal under discussion would involve
an exchange of stock in a public company for PURA's water
purification assets. PURA management would in turn issue the
purchase stock to PURA shareholders through a dividend distribution
similarly to the dividend distribution underway in conjunction with
PURA's recent sale of its cannabis cultivation assets. The
discussions at this time contemplate a new 1 for 1 dividend
distribution.
For more
information on Puration, visit https://www.purationinc.com
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024